Rice Hall James & Associates LLC Sells 16,012 Shares of OR Royalties Inc. $OR

Rice Hall James & Associates LLC reduced its stake in OR Royalties Inc. (NYSE:OR) by 12.2% in the 4th quarter, HoldingsChannel reports. The firm owned 115,728 shares of the basic materials company’s stock after selling 16,012 shares during the quarter. Rice Hall James & Associates LLC’s holdings in OR Royalties were worth $4,096,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assetmark Inc. bought a new stake in OR Royalties in the fourth quarter valued at $36,000. Caitlin John LLC bought a new stake in OR Royalties in the third quarter valued at $78,000. Allworth Financial LP increased its stake in OR Royalties by 20.0% in the fourth quarter. Allworth Financial LP now owns 2,305 shares of the basic materials company’s stock valued at $82,000 after purchasing an additional 384 shares in the last quarter. Merit Financial Group LLC bought a new stake in OR Royalties in the third quarter valued at $215,000. Finally, Flow Traders U.S. LLC bought a new stake in OR Royalties in the third quarter valued at $217,000. 68.52% of the stock is owned by institutional investors.

OR Royalties Price Performance

NYSE:OR opened at $36.20 on Tuesday. The firm has a 50-day moving average of $37.59 and a 200-day moving average of $38.76. The company has a market cap of $6.79 billion, a PE ratio of 27.01 and a beta of 0.70. OR Royalties Inc. has a one year low of $24.76 and a one year high of $48.06.

OR Royalties (NYSE:OR) last posted its earnings results on Wednesday, May 6th. The basic materials company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The company had revenue of $102.83 million during the quarter, compared to the consensus estimate of $103.27 million. OR Royalties had a net margin of 78.09% and a return on equity of 15.10%. On average, equities research analysts expect that OR Royalties Inc. will post 1.4 earnings per share for the current fiscal year.

OR Royalties Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.065 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This is a boost from OR Royalties’s previous quarterly dividend of $0.06. This represents a $0.26 annualized dividend and a dividend yield of 0.7%. OR Royalties’s payout ratio is presently 16.42%.

Analyst Ratings Changes

OR has been the subject of several research analyst reports. Weiss Ratings downgraded shares of OR Royalties from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 4th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $56.00 price target on shares of OR Royalties in a research note on Friday, April 10th. Wall Street Zen downgraded shares of OR Royalties from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Zacks Research downgraded shares of OR Royalties from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, TD Securities reissued a “hold” rating on shares of OR Royalties in a research report on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, OR Royalties presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.